Normal
Peptide technology

ImmuPharma’s innovative peptide to drug converting technology (PDCT) focuses on turning small peptides into potential drug products. 

PDCT increases a peptide’s plasma half-life and efficacy. It may improve the oral absorption of small peptides, such as met-enkephalin (the body’s internal analgesic), which would be a major advance in the development of effective medicines. 

The development risk of drugs based on peptides should be significantly reduced because the peptides are produced by the human body and are therefore less likely to be rejected.